Post-remission intervention with alemtuzumab or rituximab to eradicate minimal residual disease in chronic lymphocytic leukemia: where do we stand?

Treatment of Younger Patients with Chronic Lymphocytic Leukemia

(2011) A. Ferrajoli   Hematology-American Society of Hematology Education Program

Antigenic modulation limits the efficacy of anti-CD20 antibodies: implications for antibody selection

(2010) S. A. Beers et al.   BLOOD

Self-administered, subcutaneous alemtuzumab to treat residual disease in patients with chronic lymphocytic leukemia

(2010) William G. Wierda et al.   CANCER

Progressive Multifocal Leukoencephalopathy in Chronic Lymphocytic Leukemia: A Report of Three Cases and Review of the Literature

(2010) Anita D'Souza et al.   Clinical Lymphoma Myeloma & Leukemia

Modulation of CD20 antigen expression after rituximab treatment: A retrospective study in patients with chronic lymphocytic leukemia

(2010) Fiorella D’Auria et al.   CLINICAL THERAPEUTICS

Hepatitus B virus reactivation in HBV-DNA negative and positive patients with hematological malignancies

(2010) Münci Yağcı et al.   Hematology

Consolidation Therapy With Subcutaneous Alemtuzumab After Fludarabine and Rituximab Induction Therapy for Previously Untreated Chronic Lymphocytic Leukemia: Final Analysis of CALGB 10101

(2010) Thomas S. Lin et al.   JOURNAL OF CLINICAL ONCOLOGY

Rituximab Maintenance Treatment of Relapsed/Resistant Follicular Non-Hodgkin's Lymphoma: Long-Term Outcome of the EORTC 20981 Phase III Randomized Intergroup Study

(2010) Marinus H.J. van Oers et al.   JOURNAL OF CLINICAL ONCOLOGY

Addition of rituximab to fludarabine and cyclophosphamide in patients with chronic lymphocytic leukaemia: a randomised, open-label, phase 3 trial

(2010) M Hallek et al.   LANCET

Rituximab maintenance for 2 years in patients with high tumour burden follicular lymphoma responding to rituximab plus chemotherapy (PRIMA): a phase 3, randomised controlled trial

(2010) Gilles Salles et al.   LANCET

Immune recovery after fludarabine–cyclophosphamide–rituximab treatment in B-chronic lymphocytic leukemia: implication for maintenance immunotherapy

(2010) L Ysebaert et al.   LEUKEMIA

Phase II study of immunomodulation with granulocyte-macrophage colony-stimulating factor, interleukin-2, and rituximab following autologous stem cell transplant in patients with relapsed or refractory lymphomas

(2010) Xavier Poiré et al.   LEUKEMIA & LYMPHOMA

Alemtuzumab maintenance may safely prolong chemotherapy-free intervals in chronic lymphocytic leukemia

(2010) Matthew S. Kaufman et al.   MEDICAL ONCOLOGY

Late-Onset Neutropenia After Rituximab Treatment

(2010) Ofir Wolach et al.   MEDICINE

Rituximab-Associated Infections

(2010) Juan C. Gea-Banacloche   SEMINARS IN HEMATOLOGY

Antigenic Modulation and Rituximab Resistance

(2010) Ronald P. Taylor et al.   SEMINARS IN HEMATOLOGY

Improvement of Rituximab Efficiency in Chronic Lymphocytic Leukemia by CpG-Mediated Upregulation of CD20 Expression Independently of PU.1

(2009) Amani Mankaï et al.   Annals of the New York Academy of Sciences

Enhancing the Action of Rituximab in Chronic Lymphocytic Leukemia by Adding Fresh Frozen Plasma

(2009) Abraham Klepfish et al.   Annals of the New York Academy of Sciences

Circulating CD52 and CD20 levels at end of treatment predict for progression and survival in patients with chronic lymphocytic leukaemia treated with fludarabine, cyclophosphamide and rituximab (FCR)

(2009) Gheath Alatrash et al.   BRITISH JOURNAL OF HAEMATOLOGY

Chemoimmunotherapy may overcome the adverse prognostic significance of 11q deletion in previously untreated patients with chronic lymphocytic leukemia

(2009) Apostolia-Maria Tsimberidou et al.   CANCER

Fractionated subcutaneous rituximab is well-tolerated and preserves CD20 expression on tumor cells in patients with chronic lymphocytic leukemia

(2009) G. Aue et al.   HAEMATOLOGICA

Rituximab, Fludarabine, Cyclophosphamide, and Mitoxantrone: A New, Highly Active Chemoimmunotherapy Regimen for Chronic Lymphocytic Leukemia

(2009) Francesc Bosch et al.   JOURNAL OF CLINICAL ONCOLOGY

Pre-Emptive Treatment With Rituximab of Molecular Relapse After Autologous Stem Cell Transplantation in Mantle Cell Lymphoma

(2009) Niels S. Andersen et al.   JOURNAL OF CLINICAL ONCOLOGY

Rituximab Maintenance for the Treatment of Patients With Follicular Lymphoma: Systematic Review and Meta-analysis of Randomized Trials

(2009) Liat Vidal et al.   JNCI-Journal of the National Cancer Institute

Standardized MRD flow and ASO IGH RQ-PCR for MRD quantification in CLL patients after rituximab-containing immunochemotherapy: a comparative analysis

(2009) S Böttcher et al.   LEUKEMIA

Incorporating the use of GM-CSF in the treatment of chronic lymphocytic leukemia

(2009) Alessandra Ferrajoli   LEUKEMIA & LYMPHOMA

Fludarabine, cyclophosphamide, mitoxantrone plus rituximab (FCM-R) in frontline CLL

(2009) Stefan Faderl et al.   LEUKEMIA RESEARCH

Rituximab (B-cell depleting antibody) associated lung injury (RALI): A pediatric case and systematic review of the literature

(2009) Martin Bitzan et al.   PEDIATRIC PULMONOLOGY

State-of-the-art treatment of chronic lymphocytic leukemia

(2009) M. Hallek   Hematology-American Society of Hematology Education Program

EBV-positive immunodeficiency lymphoma after alemtuzumab-CHOP therapy for peripheral T-cell lymphoma

(2008) H. C. Kluin-Nelemans et al.   BLOOD

Long-term results of the fludarabine, cyclophosphamide, and rituximab regimen as initial therapy of chronic lymphocytic leukemia

(2008) C. S. Tam et al.   BLOOD

Guidelines for the diagnosis and treatment of chronic lymphocytic leukemia: a report from the International Workshop on Chronic Lymphocytic Leukemia updating the National Cancer Institute-Working Group 1996 guidelines

(2008) M. Hallek et al.   BLOOD

Tumor burden influences exposure and response to rituximab: pharmacokinetic-pharmacodynamic modeling using a syngeneic bioluminescent murine model expressing human CD20

(2008) D. Dayde et al.   BLOOD

Consolidation with alemtuzumab improves progression-free survival in patients with chronic lymphocytic leukaemia (CLL) in first remission - long-term follow-up of a randomized phase III trial of the German CLL Study Group (GCLLSG)

(2008) Carmen D. Schweighofer et al.   BRITISH JOURNAL OF HAEMATOLOGY

Combination therapy with fludarabine and rituximab followed by alemtuzumab in the first-line treatment of patients with chronic lymphocytic leukemia or small lymphocytic lymphoma

(2008) John D. Hainsworth et al.   CANCER

Fludarabine, Cyclophosphamide, and Mitoxantrone as Initial Therapy of Chronic Lymphocytic Leukemia: High Response Rate and Disease Eradication

(2008) F. Bosch et al.   CLINICAL CANCER RESEARCH

Lenalidomide Enhances Natural Killer Cell and Monocyte-Mediated Antibody-Dependent Cellular Cytotoxicity of Rituximab-Treated CD20+ Tumor Cells

(2008) L. Wu et al.   CLINICAL CANCER RESEARCH

Sequential Therapy With Fludarabine, High-Dose Cyclophosphamide, and Rituximab in Previously Untreated Patients With Chronic Lymphocytic Leukemia Produces High-Quality Responses: Molecular Remissions Predict for Durable Complete Responses

(2008) Nicole Lamanna et al.   JOURNAL OF CLINICAL ONCOLOGY

Chemoimmunotherapy With Low-Dose Fludarabine and Cyclophosphamide and High Dose Rituximab in Previously Untreated Patients With Chronic Lymphocytic Leukemia

(2008) Kenneth A. Foon et al.   JOURNAL OF CLINICAL ONCOLOGY

Monoclonal Antibodies for the Treatment of Hematologic Malignancies: Schedule and Maintenance Therapy

(2008) Alden Moccia et al.   SEMINARS IN HEMATOLOGY